Basilea Pharmaceutica AG

The 'Meningitis - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of meningitis clinical trials, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, providing insights into global clinical trials landscape and enrollment trends.

Innoviva Specialty Therapeutics secures exclusive U.S. distribution and licensing rights for Zevtera® (ceftobiprole) from Basilea Pharmaceutica. The FDA-approved antibiotic is the only MRSA cephalosporin for treating adult patients with Staphylococcus aureus bloodstream infections and endocarditis. The agreement includes a $4 million upfront payment plus tiered royalties and sales milestones, with a planned commercial launch in mid-2025.

The osteomyelitis market report forecasts significant growth (2019-2032) in 7MM, driven by increasing prevalence and new therapies. Key companies include Durata Therapeutics, Allergan, Basilea Pharmaceutica, and Adaptive Phage Therapeutics. Major therapies are DALVANCE, Lefamulin, CF 296, and bacteriophage therapy. The market is expected to surge due to unmet needs and pipeline advancements.

Basilea Pharmaceutica initiated the FAST-IC phase 3 study to evaluate fosmanogepix, a novel antifungal therapy inhibiting the Gwt1 enzyme, for treating candidemia and invasive candidiasis. The study compares fosmanogepix to caspofungin, with plans to enroll 450 patients globally. Basilea also plans a second phase 3 study for invasive mold infections.